Medical Crossfire®: Schizophrenia and Bipolar Disorder: Barriers to Care, Therapeutic Updates, and Best Practices

Released On
September 28, 2018

Expires On
September 28, 2019

Media Type

Completion Time
90 minutes

Psychiatry, Case Management, Home Care, Integrative Medicine, Primary Care

Schizophrenia and Bipolar Disorder

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

Supported by an educational grant from Indivior Inc.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)
  • Nurses — 1.5 contact hour(s) which includes 0.00 hour(s) of pharmacology.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational program is directed toward nurses interested in the management of patients with cancer. Other healthcare professionals interested in the management of patients with cancer are also invited to attend.

Program Overview

Schizophrenia affects an estimated 21 million people worldwide, and BPD is the sixth leading cause of disability. These are chronic psychiatric illnesses that require long-term care, and place significant health and economic burdens on patients and their families. In recent decades, the distinct separation of these 2 illnesses has weakened, and the medical literature now recognizes a partial genetic overlap between schizophrenia and BPD. Unfortunately, both schizophrenia and BPD are difficult to treat and are associated with substantial morbidity and mortality, particularly when suboptimally treated. Lack of consistent adherence to treatment is also a significant issue; however, new formulations and medications that may improve adherence have been recently approved or are under development.

During this Medical Crossfire®, a panel of expert faculty will review the burdens of illness associated with BPD and schizophrenia, along with the roles of the primary care physician in screening and management of these disorders. Additional discussions will include strategies to help improve adherence and recent data on new and emerging agents for people with BPD or schizophrenia.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Discuss the burden associated with schizophrenia.
  • Explain the burden associated with BPD.
  • Describe strategies to improve poor adherence associated with schizophrenia and BPD.
  • Identify new and emerging agents seeking to improve outcomes in patients with schizophrenia or BPD.


Joseph R. Calabrese, MD

Director, Mood Disorders Program
Bipolar Disorders Research Chair
Department of Psychiatry
University Hospitals Cleveland Medical Center
Professor, Department of Psychiatry
Case Western Reserve University School of Medicine
Cleveland, Ohio

Christoph U. Correll, MD

Professor of Psychiatry and Molecular Medicine
The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Hempstead, New York

Paul P. Doghramji, MD, FAAFP

Family Physician, Collegeville Family Practice
Medical Director, Health Services; Ursinus College
Collegeville, Pennsylvania

Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP

Director, Psychiatric Mental Health Nurse Practitioner (Lifespan) Specialty
Vanderbilt University School of Nursing
Nashville, Tennessee

Accreditation Statement

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians' Education Resource®, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.5 Contact Hours.

Disclosures of Conflicts of Interest

Joseph R. Calabrese, MD

  • Grant/Research Support: Janssen Research & Development, LLC
  • Consultant: Alkermes, Inc., Janssen Research & Development, LLC., Lundbeck, Otsuka; Pharmaceutical Development & Commercialization, Inc.

Christoph U. Correll, MD

  • No relevant financial information to disclose

Paul P. Doghramji, MD, FAAFP

  • No relevant financial information to disclose

Dawn Vanderhoef, PhD, DNP, PMHNP-BC, FAANP

  • No relevant financial information to disclose

The staff of Physicians' Education Resource®, LLC, (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for This Activity and Receiving Credit

  1. You will need to log in to participate in the activity.
  2. Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  3. At the end of the activity, educational content/audio files will be available for your reference.
  4. In order to receive a CME/CE certificate, you must complete the activity.
  5. Complete the Posttest and pass with a score of 70% or higher, complete the Evaluation, and then click on “Request for Credit.” You may immediately download a CME/CE certificate upon completion of these steps.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME/CE activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME/CE activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This CME/CE activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME/CE activity is for continuing medical and nursing education purposes only, and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER®.